Italy-based Angelini Pharma announced a $4.1 billion acquisition of Catalyst Pharmaceuticals, a deal that marks the company’s long-anticipated entry into the United States healthcare market. The transaction instantly positions Angelini as a more influential player in the global biopharmaceutical landscape while giving the European company a direct foothold in one of the world’s largest and most profitable pharmaceutical markets. The acquisition reflects more than a simple cor
